Decorative Graphic
Important Notice
This Inari Medical website and all product offerings listed are tailored for the United States only. Please be aware that product availability and regulatory claims may vary in other regions we serve, including Europe, the Middle East, and Africa (EMEA), Asia-Pacific (APAC), and Latin America/Canada. Inari Medical is currently developing separate websites for our products tailored to these other global and regional markets.
Decorative Graphic
Venous
Thromboembolism
+ Cancer
CANCER AND THE RISK OF BLOOD CLOTS
Research has shown that there is a strong connection between cancer and VTE. Genetic changes that cause cancer and many chemotherapy drugs are thought to contribute to the increased risk of VTE in patients with cancer.
Patients with cancer are 5X more likely
to develop a blood clot.1
UNDERSTANDING BLOOD CLOTS
A blood clot in one of the large veins, usually in a person’s leg or arm, is called deep vein thrombosis, or DVT. When a DVT forms, it can partially or completely block the flow of blood through the vein. If DVT is not treated, the clot can break off and travel to the lungs, causing a PE.
A blood clot in the lungs is called pulmonary embolism, or PE. This requires immediate medical attention because a PE can be deadly.
WHY DO PEOPLE WITH
CANCER HAVEA HIGHER RISK FOR BLOOD CLOTS?
More than 900,000 people in the United States get blood clots each year, but patients with cancer
are amongst the most at risk for developing a blood clot. Some of the reasons for this are:
1 in 5
  • The genetic changes that cause cancer and the drugs used to fight cancer can increase the activity of clotting factors in the blood.
  • Tissue damage that can be caused by cancer may start the blood clotting process.
Certain types of cancers can also increase a patient’s risk for blood clots, including:
  • Acute Leukemia
  • Glioblastoma
  • Kidney cancer
  • Lung cancer
  • Pancreatic cancer
  • Metastatic cancer (cancer that has spread from where it started to other areas)
Learn more about the risk factors for blood clots
HOW CAN I PROTECT MYSELF FROM A BLOOD CLOT WHILE BEING TREATED FOR CANCER?
  • Become familiar with the signs and symptoms of blood clots
  • Consider your elevated risk factors (type of cancer, type of cancer treatment)
  • Consult with your doctor to create a blood clot prevention plan
Where can I learn more about cancer and blood clots?
American Cancer Society, National Blood Clot Alliance
The information, including but not limited to, text, graphics, images and other material contained on this website are for informational purposes only. No material on this site is intended to be a substitute for professional medical advice, diagnosis or treatment.

Sources:

1. Fennerty, A. Venous thromboembolic disease and cancer. Postgraduate Medical Journal 2006 Oct; 82:642-648.
2. CDC: https://www.cdc.gov/ncbddd/dvt/materials/cancer-and-blood-clots.html

Indications for Use:
The FlowTriever® system is indicated for (1) the non-surgical removal of emboli and thrombi from blood vessels and (2) injection, infusion and/or aspiration of contrast media and other fluids into or from a blood vessel. The FlowTriever system is intended for use in the peripheral vasculature and for the treatment of pulmonary embolism. Triever catheters are intended for use in treating clot in transit in the right atrium but not in conjunction with FlowTriever catheters. The FlowTriever2® catheter is intended for use in the peripheral vasculature. The FlowSaver® blood return system is used with Triever catheters for autologous blood transfusion. The ClotTriever® Thrombectomy System is indicated for: (1) The non-surgical removal of thrombi and emboli from blood vessels. (2) Injection, infusion, and/or aspiration of contrast media and other fluids into or from a blood vessel. The ClotTriever Thrombectomy System is intended for use in the peripheral vasculature including deep vein thrombosis (DVT). The ClotTriever Sheaths are indicated for use as a conduit for the insertion of endovascular devices into the vasculature while minimizing blood loss associated with such insertions.